XBIO · Xenetic Biosciences, Inc.
$3.59
+0.20 (+5.90%)
At close · Aug 21
Market Cap
$8.41M
Shares
2.34M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.59
Open$3.36
Day$3.18–3.73
52W close$2.02–10.36
Avg vol 30d52K
Short int11K · 0.5% float · 1.0d
Short vol31%
DataMay 2023–Aug 2026
Filing10-Q · Aug 6
Raw chart and full-history price indicators begin at the captured split on May 15, 2023; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+31%
above
Price vs 50-day avg
+23%
above
RSI (14)
74
overbought
MACD trend
Positive
52-week position
19%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+36%
trailing
6-month return
+41%
trailing
YTD return
+65%
this year
Relative strength
+29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+33% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.48% of float · ▼ -41.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
8 holders — mid 3-yr range
Squeeze score
33
low risk · 0–100
Fundamentals
Revenue growth
+19%
Y/Y
Gross margin
0%
contracting
EPS growth
+39%
Y/Y
Free cash flow
$-2.3M
Balance sheet
$212.8K
net debt
Quant / Vol
risk profile
Volatility
166%
annualized · 1-yr
Max drawdown
−81%
past year
ATR
5.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+31%
Bullish
Price vs 50-day avg
+23%
Bullish
RSI (14)
74
Bearish
MACD trend
Positive
Bullish
52-week position
19%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+33% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.48% of float · ▼ -41.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
8 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $4 · 19%
Range high $10
vs 200-day avg +31%
vs 50-day avg +23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XBIO
this stock
Xenetic Biosciences, Inc.
|
$8.41M | +65.4% | +19.0% | — | 0.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
Raw-price comparisons begin at the captured split on May 15, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XBIO | +9.5% | +36.0% | +40.8% | +41.6% | +65.4% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +10.8% | +32.4% | +29.2% | +39.1% | +53.2% |